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Summary
 Aim To assess the relationship between pre-therapeutic serum TPS and VEGF levels and the results of 
treatment as measured immediately after completion of therapy.
 Materials/Methods The study included 146 women treated for cancer of the uterine cervix. Of these, 37 women were 
in stage I, 43 in stage II, 59 in stage III and 7 in stage IV of disease progression according to the 
FIGO classiﬁ cation. The ages of the patients ranged from 31 to 80 years. The dominant cancer ob-
served was squamous cell carcinoma which accounted for more than 97% of cases. Samples were 
taken before commencement of treatment. Patients were treated by a combination of methods in-
cluding radiochemotherapy, radical radiotherapy and palliative radiotherapy. The effects of ther-
apy were graded after completion of irradiation according to generally accepted criteria. For test-
ed criteria, ROC curves were drawn, determining cut-off points of 58 U/l for TPS and 500 pg/l for 
VEGF. For statistical calculations the U Mann-Whitney test was used.
 Results The level of VEGF expression varied between groups of patients in certain stages of disease progres-
sion (stages 1 & 2 and stages 2 & 3). Statistically signiﬁ cant differences were found between group 
PR in stage 2 and a control group of healthy women. Entry levels of TPS rose with tumor advance-
ment (in stages 2, 3 & 4) and were higher than in a group of healthy women. Detected differenc-
es were statistically signiﬁ cant.
 Conclusions Only pre-therapeutic TPS levels show deﬁ nite differences between degrees of clinical advancement 
and also with early therapeutic effects. Comparatively higher levels of serum TPS were found in 
patients with the worst prognosis prior to treatment (group P) than in the control group. This dif-
ference is statistically signiﬁ cant. Pre-therapeutic VEGF levels showed statistically signiﬁ cant differ-
ences between early (I, II) and advanced (III) clinical stages of the tumor as well as some effects 
of therapy assessed immediately after completion of treatment (PR vs S).
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BACKGROUND
Cancer of the uterine cervix is characterized by long, 
localized , slow growth and occasionally, under conducive 
conditions, sudden accelerations in the tumor growth proc-
ess. This process, as in other cancers, is closely related to 
increased angiogenesis and the ability to form metastases. 
Low immunogeneity of the cancer, and many levelled dis-
turbances of connected processes of the immunological re-
sponse, manifest themselves as the clinical aggressiveness 
of the cancer.
Characteristic pathomorphological features of a malignant 
tumor (structure, type, degree of differentiation) prede-
termine the course of the disease process. Many connect-
ed factors inﬂ uence the ﬁ nal therapeutic effects on can-
cers of the uterine cervix and it is necessary to deﬁ ne their 
prognostic signiﬁ cance.
The growth of a malignant tumor is dependent on the dis-
tribution of necessary substances and equally on the re-
moval of waste products from the environment of the neo-
plasm. Many clinical connections have been demonstrated 
between the vascularisation of a tumor and its aggression 
[1,2]. Under physiological conditions, angiogenesis is a 
complicated process, regulated by stimulatory and inhib-
itory mechanisms. Under pathological conditions these 
mechanisms are either damaged or do not function at all 
[3]. One of the factors regulating angiogenesis is Vascular 
Endothelial Growth Factor (VEGF) [4]. VEGF is a glycopro-
tein, which has the ability to bind heparin, and comprises 
at least 5 isoforms known as VEGF 121, VEGF 165, VEGF 
189 and VEGF 205. The ﬁ fth isoform and its role in the 
process of angiogenesis has not been completely explored. 
The ﬁ gures in each isoform name represent the number of 
amino acids each isoform contains [2]. Induction of VEGF 
dependent permeability is reliant on the penetration of 
certain protein isomers to the interstitium, from which en-
dothelial cells later migrate. The VEGF receptors present on 
the above cells may be divided into three sub-types: FLT-1, 
FLK-1/KDR and VEGFR-3/FLT-4. Interactions between the 
VEGF family and its receptors initiate many processes: ang-
iogenesis, lymph vessel and capillary formation, activation 
of enzymes in endothelial cells responsible for invasion of 
the stroma, endothelial cell mitosis and, as a consequence, 
the formation of new vessels in and around the tumor by 
several different methods [5]. Many tumors of the uterine 
cervix express high levels of VEGF, including some rare 
glandular cancers [6].
TPS (Tissue Polypeptide Speciﬁ c Antigen) is a well known 
tumor proliferation marker [7]. It is created and secret-
ed into the blood from late phase S to phase M. The best 
known is TPA which is made up of 35 epitopes, of which 
only 2 decide its speciﬁ city [8]. A fragment of cytokeratin 
18 weighing 14kD, TPS may be identiﬁ ed by immunoen-
zymatic reactions through the use of the monoclonal anti-
body M3 [9,10]. Increased levels of TPS in the serum and 
effusion ﬂ uid may be observed in cases of ovarian cancer 
and other gynaecological tumors [11].
The proteins mentioned above directly or indirectly take 
part in, and therefore provide information about, the proc-
esses of tumor growth [1,12–19].
AIM
The purpose of the study was to assess the relationship be-
tween pre-treatment TPS and VEGF levels in the serum of 
patients, with invasive cancer of the uterine cervix, and the 
results of treatment – as assessed immediately after com-
pletion of therapy.
MATERIALS AND METHODS
The study included 166 women as follows: 
146 patients with invasive cancer of the uterine cervix aged 
between 31 and 80 years (average age 53.12 – standard de-
viation 11.04),
20 healthy women to form control group “S” (Sanus) aged 
between 30 and 76 years (average age 49.7 – standard de-
viation 14.10).
The ages of women in the control group was adequate for the 
study group and socio-economic conditions were similar.
Cancer of the uterine cervix was classiﬁ ed into 4 stages of 
clinical advancement, from IB to IVB, according to the cri-
teria of the International Federation of Gynaecology and 
Obstetrics (FIGO), and in agreement with the TNM sys-
tem.
Stage 1 was represented in the study by 37 cases (25.34%) 
while 43 patients (29.45%) were classiﬁ ed as being in stage 
II of clinical advancement. Stages III and IV were repre-
sented by 59 (40.41%) and 7 (4.79%) cases respectively. 
(Table 1).
The microscopic structure of the tumors was graded accord-
ing to the criteria of the World Health Organization.
Among the investigated women, the most commonly ob-
served tumor was non-keratinising squamous cell carcinoma, 
although other malignancies were observed (Table 2).
Prior to commencement of oncological therapy, 5 ml 
of blood was taken from each patient. The blood was 
centrifuged (1200 × g) and the resulting serum frac-
tion was frozen and stored at –20°C. In order to identi-
fy proteins, immunoenzymatic methods were used – in 
the form of commercially prepared tests: TPS-Biotech, 
Broma, Sweden, ELISA-Kit, VEGF165-R&D System, 
Quantikine, ELISA-Kit. The above tests were performed 
in the Department of Tumor Immunology of Wrocław 
Medical University.
Degree of clinical 
advancement Number %
I  37  25.34
II  43  29.45
III  59  40.41
IV  7  4.79
Table 1. Patient characteristics (Clinical advancement of the tumor).
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Patients were treated in the years 2001 and 2002 in the 
Gynaecological Oncology Clinic of Wrocław Medical 
University if they satisﬁ ed the requirements for one of the 
following treatment schemes: 
•  surgical treatment (modiﬁ ed Wertheim-Meigs procedure) 
with follow-up complementary radiotherapy.
•  a combination of 2 methods of radical radiotherapy 
– brachytherapy (Selektron Cs-137 MDR/LDR) with tel-
etherapy (Megavolt 4,6,9,18 MeV).
•  radical radiotherapy (as above) in combination with sin-
gle drug chemotherapy – based on cisplatin at a dosage 
of 40 mg/m2, once weekly – 6 courses.
•  radiochemotherapy with subsequent surgical treatment.
• palliative radiotherapy.
The effects of therapy were graded immediately after com-
pletion and according to accepted criteria: CR, PR, SD, P.
For each investigated parameter, an ROC curve was drawn 
in order to establish cut-off points. These were 500 pg/l for 
VEGF and 58 U/l for TPS.
For statistical analysis, the non-parametric U Mann-Whitney 
test was applied.
RESULTS
Comparison of TPS levels between individual stages of clin-
ical advancement (Figure 1): 
•  I vs III – a difference in TPS levels was demonstrated 
(p=0.000069).
•  I vs IV – a difference in TPS levels was demonstrated 
(p=0.027957).
•  I vs S – a difference in TPS levels was demonstrated 
(p=0.014306).
•  II vs III – a difference in TPS levels was demonstrated 
(p=0.012053).
•  II vs S – a difference in TPS levels was demonstrated 
(p=0.000106).
•  III vs S – a difference in TPS levels was demonstrated 
(p=0.000000).
•  IV vs S – a difference in TPS levels was demonstrated 
(p=0.000604).
Similarly, for VEGF (Figure 2):
•  I vs III – a difference in VEGF levels was demonstrated 
(p=0.036715).
•  II vs III – a difference in VEGF levels was demonstrated 
(p=0.021804).
Comparison of TPS concentration levels in study groups 
and the control group ‘S’ (Figure 3): 
•  CR vs S – a difference in TPS levels was demonstrated 
(p=0.021088).
•  PR vs S – a difference in TPS levels was demonstrated 
(p=0.000001).
•  SD vs S – a difference in TPS levels was demonstrated 
(p=0.028467).
•  P vs S – a difference in TPS levels was demonstrated 
(p=0.000220).
•  CR vs PR – a difference in TPS levels was demonstrated 
(p=0.000168).
•  CR vs P – a difference in TPS levels was demonstrated 
(p=0.006213).
Owing to early therapeutic effects at certain stages of clin-
ical advancement, the following results were obtained for 
TPS (Figure 4):
•  In stage I of clinical advancement – according to the FIGO 
classiﬁ cation:
 –  CR vs P – a difference in TPS levels was demonstrated 
(p=0.038786).
Group Histopathology Number %
A Ca plano. Akeratodes  52  37.14
B Ca plano. G-2 Keratodes  15  10.71
C Ca plano. G-2 (Ak/Ke)  30  21.43
D Ca plano. G-3 (indif/nondif/maledif)  15  10.71
E Adenocarcinoma  4  2.86
F Ca plano. (nonspecifi c structure)  24  17.14
Table 2. Patient characteristics (Histopathology).
Stage of clinical advancement according to FIGO
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Figure 1. Ranges and median values for TPS concentration levels in each 
degree of clinical advancement and in control group ‘S’.
Rusiecka M et al – TPS and VEGF concentrations in cancer of the uterine cervix
3
Original Paper
Therapeutic effect 
TP
S
CR                   PR                   SD                    P        Control group
1200 
1000 
800 
600 
400 
200 
0
Min-Maks.
25%-75%
Median
Figure 3. Ranges and median values for TPS concentration levels in groups 
(as defi ned by early results of treatment) and in the control group ‘S’.
Stage of clinical advancement according to FIGO
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Figure 2. Ranges and median values for VEGF concentration levels in 
each degree of clinical advancement and in control group ‘S’.
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Figure 4 (a,b,c,d). Ranges and median values for TPS concentration levels in groups (as defi ned by early results of treatment and stage of clinical 
advancement).
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 –  P vs S – a difference in TPS levels was demonstrated 
(p=0.016383).
•  In stage II of clinical advancement – according to the 
FIGO classiﬁ cation:
 –  CR vs S – a difference in TPS levels was demonstrated 
(p=0.004749).
 –  PR vs S – a difference in TPS levels was demonstrated 
(p=0.000195).
•  In stage III of clinical advancement – according to the 
FIGO classiﬁ cation:
 –  CR vs S – a difference in TPS levels was demonstrated 
(p=0.001721).
 –  PR vs S – a difference in TPS levels was demonstrated 
(p=0.000000).
•  In stage IV of clinical advancement – according to the 
FIGO classiﬁ cation:
 –  PR vs S – a difference in TPS levels was demonstrated 
(p=0.022485).
 –  P vs S – a difference in TPS levels was demonstrated 
(p=0.004160).
Similarly for VEGF (Figure 5):
•  In stage II of clinical advancement – according to the 
FIGO classiﬁ cation: 
 –  PR vs S – a difference in VEGF levels was demonstrat-
ed (p=0.030236).
DISCUSSION
Expression of VEGF mRNA in tumor tissues (cancers of the 
breast, lung, kidney, stomach, ovary, vulva and corpus and cer-
vix of the uterus) has been the subject of many clinical stud-
ies [1,19–22]. In the case of cancer of the cervix of the uter-
us, both in situ and microinvasive tumors have been studied 
[18,23,24]. Attention is drawn to the fact that VEGF expres-
sion is proportional to tumor growth: in situ – microinvasion – 
macroinvasion, but only to a certain point. In clinical advance-
ment stages III and IVa, according to the FIGO classiﬁ cation, 
VEGF levels suddenly drop [25]. An exception is stage IVB 
in which there is a general spread of processes, for example, 
metastasis via the blood vessels. The processes of angiogen-
esis, proliferation and spread play equally important roles, 
at this stage, in the breakdown of the majority of the body’s 
defence systems [26]. The described phenomena are reﬂ ect-
ed in the concentration levels of VEGF in patients’ serum, as 
observed in the above tests. Despite a lack of statistical signif-
icance, there exists a pattern of increasing VEGF concentra-
tion in the blood serum of patients with cancer of the uter-
ine cervix. This phenomenon partly explains increases in the 
tumor stroma and also an increased rate in breakdown proc-
esses. The percentage of hypoxic cells and necrotic masses in 
tumors increase while the number of blood vessels running 
to the centre of the tumor decreases [3,5]. Advanced cancer 
of the uterine cervix is characterized by long local growth, 
with no blood-borne spread, in which intensive angiogenesis 
plays a secondary role; this situation is reversed in the cases 
of cancers of the ovarys and the corpus of the uterus. Both 
tumors, which are glandular in nature and are well perfused 
with blood (for reproductive function), have a tendency to 
spread within the peritoneal cavity, during the early clinical 
stages of the disease, generally via cell migration, lymph ves-
sels and via the capillaries. In advanced cancer of the corpus 
Figure 5 (a,b,c,d). Ranges and median values for VEGF concentration levels in groups (as defi ned by early results of treatment and stage of clinical 
advancement) present with several small gallstones (arrow).
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of the uterus, and especially in ovarian cancer with peritoneal 
spread, VEGF levels are always high [27,28]. A point worth 
noting is that the pre-therapeutic values for VEGF levels are 
reﬂ ected in the early therapeutic effects on cancers of the 
uterine cervix. Besides surgery, radio and chemotherapy are 
also used. Applied schemes must be maximally effective and 
appropriate to the clinical stage of the tumor and its micro-
scopic structure. Both methods of threatment have effects 
on occurrence of apoptosis in tumor cells. VEGF plays the 
role of inhibiting apoptotic cell death in haemopoietic cells 
after radio and chemotherapy, under laboratory conditions 
[5,29]. High levels of VEGF should be inversely proportion-
al to the measured effects [30,31].
This simple relationship is complicated by sudden tumor 
growth – rapid proliferation is dependent on vascularisa-
tion (reoxygenation in chemo and radiotherapy) [3,32]. 
Reoxygenation creates good conditions for therapy, but also 
for the repopulation of tumor cells. In clinical practice, rap-
id tumor proliferation responds well to applied therapies al-
though, unfortunately, after completion of therapy, rapid re-
currence also occurs [5,31]. There should be a measurable 
relationship between VEGF levels and the degree of differ-
entiation of the tumor. In solid tumors, growth of the stro-
ma results in decreases in angiogenetic factors. Additional 
interpretative complications arise from both early and late 
radiation reactions: patients in group PR (partial remis-
sion) are sometimes later included in group CR (complete 
remission) after postirradiation reactions recede. From the 
point of view of clinical oncology the results of treatment 
are easier to grade after 2,3 or 5 years, when the effects of 
radiation have passed and the frequency of complications 
has fallen. (After 5 years recurrence of cancer of the uter-
ine cervix occurs very rarely.)
In the case of TPS levels, it is evident that secretion is related 
to DNA synthesis, protein synthesis and cell division. In this as-
pect, TPS may be correlated with both the number of tumor 
cells present and with stroma growth [7,9,12,33]. Logically, 
there should be a close relationship between the clinical stage 
of the tumor, its degree of differentiation, and its clinical ag-
gression. In the above tests, TPS was used as a well known 
proliferation marker involved in many tumor processes. It is 
synthesized and released into the circulatory system from late 
in phase S to phase M of the cell cycle which, along with the 
characteristic growth and course of disease in cancers of the 
uterine cervix, is reﬂ ected in the results. These results are in 
agreement with those of other authors [7,12,14–17]. Because 
grading of early therapeutic effects is closely related to the 
observation (or lack thereof) of pre-existing inﬁ ltration, the 
results may conﬁ rm the ﬁ nal clinical diagnosis.
It should be underlined that the more complicated the ob-
served process is, the harder it becomes to separate test pa-
rameters from the cascade of factors responsible for promo-
tion or inhibition of the tumor. It is much easier to conﬁ rm 
the relationship between factors indirectly related to each 
other than between discrete factors controlling the phenom-
ena of oncogenesis or destruction of the tumor. Many aspects 
are still not fully understood with regard to the course of 
malignant diseases through time and to changes in endog-
enous and exogenous factors. Further testing is required 
in order to deﬁ ne independent prognostic factors for new 
methods in prophylaxis and therapy.
CONCLUSIONS
1.  TPS can be used to differentiate, to a statistically signif-
icant degree, between stages of clinical advancement in 
cancer of the uterine cervix. Furthermore, there exists 
a statistically signiﬁ cant difference between results from 
patients in each stage of clinical advancement, relative to 
a contol group.
2.  Also observed was a statistical difference between pre-
therapeutic TPS concentrations in the control group and 
each group of therapeutic effects.
3.  Both the tested parameters can identify stage III of clinical 
advancement in cases of cancer of the uterine cervix.
4.  The expression level of VEGF in the blood serum of pa-
tients with cancer of the uterine cervix increases in line 
with stage of clinical advancement. This increase is not 
statistically signiﬁ cant.
5.  The level of VEGF identiﬁ ed pre-therapeutically in patients 
with cancer of the uterine cervix shows correlation with 
early therapeutic effects only in certain clinical stages.
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